Eli Lilly (LLY)
(Delayed Data from NYSE)
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $886.00 -1.16 (-0.13%) 6:14 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $886.00 -1.16 (-0.13%) 6:14 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway
by Zacks Equity Research
Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Thermo Fisher Scientific & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO) and Lockheed Martin Corporation (LMT).
Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.
J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.
Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View
by Kinjel Shah
FDA issues CRL to Eli Lilly's (LLY) BLA seeking approval of mirikizumab for ulcerative colitis (UC). Novo Nordisk (NVO) ups sales and profit outlook for 2023.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $375.15, marking a +1.65% move from the previous day.
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.
Alexandria (ARE) Transfers Partial Interest in 15 Necco Street
by Zacks Equity Research
Amid the solid demand for high-quality life science assets, Alexandria (ARE) closes the strategic partial interest transaction for 15 Necco Street to a U.S. affiliate of Mori Trust Co., Ltd.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
3 Sector ETFs to Play as Recession Fears Are on the Rise
by Yashwardhan Jain
With recession fears on the rise, look into some sectors that can shield from market volatility.
Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $368.29, marking a +1.67% move from the previous day.
Why Lilly (LLY) Could Beat Earnings Estimates Again
by Zacks Equity Research
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $337.65, marking a +0.91% move from the previous day.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly
by Zacks Equity Research
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
by Kinjel Shah
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
The Zacks Analyst Blog Highlights Lilly, Honeywell International. American Express, Lowe's Companies and Airbnb
by Zacks Equity Research
Lilly, Honeywell International. American Express, Lowe's Companies and Airbnb are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Honeywell International & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Honeywell International Inc. (HON) and American Express Co. (AXP).
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device
by Zacks Equity Research
Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.
Here's Why You Should Add Novo (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $331.08, moving -0.76% from the previous trading session.